FrancophonIA/ELRC3.0 huggingface dataset:
English: When prescribing Levviax, consideration should be given to official guidance on the appropriate use of antibacterial agents.
Estonian: Levviax'i ordineerimisel tuleb arvesse võtta antibiootikumide kasutamise ametlikke juhiseid.
English: The frequency and severity of increased hepatic enzyme activity and liver disease appear similar to clarithromycin but justify close post-marketing surveillance, as does the potential prolongation of the QT-interval
Estonian: Maksaensüümide aktiivsuse tõusu ja maksahaiguste sagedus ja raskus näib sarnanevat klaritromütsiini puhul esinevatega, kuid seetõttu on põhjendatud hoolikas turustusjärgne järelevalve, samuti QT-intervalli võimaliku pikenemise suhtes.
English: Clinical trials, in general, support similar efficacy of telithromycin and comparators in the indications investigated (CAP not clinically serious enough to warrant parenteral therapy but efficacy has been demonstrated in a limited number of patients with risk factors such as pneumococcal bacteraemia or age higher than 65 years, AECB, sinusitis, and pharyngotonsillitis caused by S. pyogenes).
Estonian: Kliinilised uuringud toetavad üldiselt telitromütsiini ja võrreldavate ravimpreparaatide sarnast toimet uuritud näidustuste korral (keskkonnatekkene pneumoonia, mis ei ole kliiniliselt piisavalt raske, et oleks vajalik parenteraalne ravi, kuid toimet on tõendatud piiratud arvul patsientidel, kelle riskiteguriteks olid näiteks pneumokokist põhjustatud baktereemia või vanus üle 65 aasta, kroonilise bronhiidi ägenemine, sinusiit või S. pyogenes'e põhjustatud farüngotonsilliit).
English: The most common side effects are, as for macrolides, mainly reported from the digestive and nervous systems, with diarrhoea, nausea, headache and dizziness.
Estonian: Kõige sagedasemad kõrvaltoimed on nagu makroliididelgi põhiliselt seotud seedetrakti ja närvisüsteemiga - diarröa, iiveldus, peavalu ja pearinglus.
English: Authorised presentations:
Estonian: Lubatud esitusviisid:
English: Orphan medicinal product designation date:
Estonian: Harva kasutatavaks ravimiks nimetamise kuupäev:
English: The active substance of Levviax is telithromycin, an antibacterial medicinal product which is a novel semi-synthetic antibacterial agent belonging to a new family of antibiotics, the ketolides, closely related to the well-known macrolide antibiotics.
Estonian: Levviax'i toimeaine telitromütsiin on antibakteriaalne ravimpreparaat, uudne poolsünteetiline antibakteriaalne aine, mis kuulub makroliididele lähedasse uude antibiootikumide klassi - ketoliidid.
English: In patients of 18 years and older: - Community-acquired pneumonia, mild or moderate, - Acute exacerbation of chronic bronchitis, - Acute sinusitis, - Tonsillitis/pharyngitis caused by Group A beta streptococci, as an alternative when beta lactam antibiotics are not appropriate.
Estonian: 18-aastased ja vanemad patsiendid: - keskkonnatekkene pneumoonia, kerge või keskmise raskusega, - kroonilise bronhiidi ägenemine, - äge sinusiit, - A-grupi ß-streptokokkide poolt põhjustatud kui beetalaktaamantibiootikume ei ole võimalik kasutada.
English: The pharmacological action of telithromycin involves inhibition of bacterial protein synthesis and is similar to that of macrolides, but
Estonian: Telitromütsiini farmakoloogiline toime seisneb bakterite valgusünteesi pärssimises ja sarnaneb
English: Tonsillitis/pharyngitis caused by Group A beta streptococci, as an alternative when beta lactam antibiotics are not appropriate
Estonian: 12…18- aastased patsiendid: - A-grupi ß-streptokokkide poolt põhjustatud kui beetalaktaamantibiootikume pole võimalik kasutada.
English: London, 15 November 2007 Doc.
Estonian: London, 15. november 2007 Dok.
English: Ref. EMEA/519568/2007
Estonian: nr EMEA/519568/2007
English: This could have had an impact on the types of treatment chosen by doctors if they had relied on the test's results.
Estonian: See oleks võinud mõjutada ravi liike, mida arstid oleksid testi tulemustele tuginedes valinud.
English: Following the CHMP's opinion, it usually takes around two months for the European Commission to grant a licence.
Estonian: Pärast komitee otsust kulub Euroopa Komisjonil müügiloa andmiseks tavaliselt ligikaudu kaks kuud.
English: International non-proprietary name (INN): 1-13C-caprylic acid
Estonian: Rahvusvaheline mittekaubanduslik nimetus (INN): 1-13C-kaprüülhape
English: These included healthy volunteers and patients with stomach problems.
Estonian: Nende hulka kuulusid terved vabatahtlikud ja maoprobleemidega patsiendid.
English: Once the company has supplied responses to the questions, the CHMP reviews them and may, before giving an opinion, ask any remaining questions at day 180.
Estonian: Kui ettevõte on esitatud küsimustele vastanud, vaatab komitee need läbi ja võib enne otsuse tegemist esitada 180. päeval veel küsimusi.
English: This labelled carbon dioxide can be detected in breath samples taken every 15 to 30 minutes in the four hours after the test meal.
Estonian: Seda märgistatud süsinikdioksiidi võib avastada väljahingatava õhu proovides, mida võetakse nelja tunni möödumisel pärast testtoidu söömist iga 15 kuni 30 minuti järel.
English: The application was at day 200 when the company withdrew.
Estonian: Taotluse menetlemine oli kestnud 200 päeva, kui ettevõte võttis taotluse tagasi.
English: Gastromotal is a diagnostic test.
Estonian: Gastromotal on diagnostilise testi aine.
English: In the main studies, the level of agreement between Gastromotal and the standard test was too low to be acceptable, resulting in a considerable risk of false positive and false negative results.
Estonian: Põhiuuringus oli Gastromotali ja tavapärase testi kokkulangevus liiga väike, et olla vastuvõetav, ning selle tulemusena oli üsna suur oht saada vääri positiivseid või negatiivseid tulemusi.
English: The letter from the company notifying the EMEA of the withdrawal of the application is available here
Estonian: Ettevõtte kiri, milles ta teatab Euroopa Ravimiametile oma taotluse tagasivõtmisest, on avaldatud siin.
English: The rate of stomach emptying can then be determined by looking at the speed at which labelled carbon dioxide is released in the breath.
Estonian: Mao tühjenemiskiiruse saab määrata märgistatud süsinikdioksiidi hingeõhku vabanemise kiiruse põhjal.
English: What is Gastromotal?
Estonian: Mis on Gastromotal?
English: The effectiveness of Gastromotal has been compared with that of a standard test called 99Tc-scintigraphy (a type of scan using radioactive tracers) in two main studies involving a total of 310
Estonian: Gastromotali efektiivsust võrreldi tavapärase 99Tc-stsintigraafia testiga (organismi kaardistamine radioaktiivsete märgistusainetega) kahes põhiuuringus, milles osales kokku 310 täiskasvanut.
English: This means that it contains 13C, a non-radioactive, rare form of the carbon atom, instead of carbon-12 (12C), the form that is the most common in nature.
Estonian: See tähendab, et see sisaldab süsinikuaatomi looduses kõige rohkem esineva vormi süsinik-12 (12C) asemel süsinikuaatomi haruldast mitteradioaktiivset vormi 13C.
English: In both studies, the main measure of effectiveness was how long it took for half of the stomach's solid contents to be emptied.
Estonian: Mõlemas uuringus mõõdeti efektiivsust põhiliselt aja järgi, mis kulus poole tahke maosisu väljumiseks maost.
English: On 5 November 2007, INFAI, Institut für biomedizinische Analytik & NMR-Imaging GmbH officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Gastromotal, for in vivo diagnosis of solidphase gastric half emptying time in gastric motility disorders.
Estonian: 5. novembril 2007 teatas ettevõte INFAI, Institut für biomedizinische Analytik & NMR-Imaging GmbH ametlikult inimtervishoius kasutatavate ravimite komiteele oma soovist võtta tagasi ravimi Gastromotal müügiloa taotlus.
English: The active substance in Gastromotal, 1-13C-caprylic acid, is a natural chemical called caprylic acid that has been labelled with carbon-13 (13C).
Estonian: Gastromotalis toimeainena sisalduv 1-13C-kaprüülhape on looduslik keemiline kaprüülhape, mis on märgistatud süsinik-13-ga (13C).
English: When a patient takes a dose of Gastromotal mixed into a test meal, it enters the stomach with the food.
Estonian: Kui patsiendile manustada testtoiduga segatuna Gastromotali annus, liigub see koos toiduga makku.
English: It was to be available as a syringe containing a liquid for drinking, containing the active substance 1-13C-caprylic acid (90 mg).
Estonian: Seda kavatseti turustada süstlas oleva suukaudse vedelikuna (joomiseks), mis sisaldab toimeainet 1-13C-kaprüülhapet (90 mg).
English: As the food in the stomach is gradually emptied into the gut, it takes the Gastromotal with it, where it is absorbed into the blood and then broken down, releasing carbon dioxide gas labelled with 13C into the breath.
Estonian: Maos sisalduv toit väljub maost järk-järgult koos Gastromotaliga soolde, kus ravim imendub verre ja seejärel laguneb, vabastades väljahingatavasse õhku 13C-märgistusega süsinikdioksiidgaasi.
English: The CHMP was assessing the responses given by the company to a list of questions.
Estonian: Inimtervishoius kasutatavate komitee hindas sel ajal vastuseid, mida ettevõte oli küsimustele andnud.
English: What are the consequences of the withdrawal for patients undergoing clinical trials or compassionate use programmes with Gastromotal?
Estonian: Mis on tagasivõtmise mõju praegu Gastromotali kliinilistes uuringutes või eriloaga kasutamise programmides osalevatele patsientidele?
English: Therefore, at the time of the withdrawal, the CHMP's view was that a benefit of Gastromotal had not been sufficiently demonstrated and any benefits did not outweigh the identified risks.
Estonian: Inimtervishoius kasutatavate ravimite komitee oli taotluse tagasivõtmise ajal seepärast arvamusel, et Gastromotali kasulikkus ei olnud küllaldaselt tõendatud ega ületanud tuvastatud riske.
English: How is Gastromotal expected to work?
Estonian: Milline on Gastromotali eeldatav toime?
English: Gastromotal was expected to be used to diagnose delayed stomach emptying in patients with stomach problems.
Estonian: Gastromotali kavatseti kasutada mao tühjenemise aeglustumise diagnoosimiseks maoprobleemidega patsientidel.
English: The company informed the CHMP that there are no consequences for patients currently included in clinical trials or compassionate use programmes with Gastromotal.
Estonian: Ettevõte teatas inimtervishoius kasutatavate ravimite komiteele, et praegu Gastromotali kliinilistes uuringutes või eriloaga kasutamise programmides osalevatele patsientidele tagasivõtmine mõju ei avalda.
English: Based on the review of the data and the company's response to the CHMP list of questions at the time of the withdrawal, the CHMP had some concerns and was of the provisional opinion that Gastromotal could not have been approved for the diagnosis of delayed stomach emptying.
Estonian: Tuginedes esitatud andmete analüüsile ja ettevõtte vastustele inimtervishoius kasutatavate ravimite komitee poolt esitatud küsimustele, nägi inimtervishoius kasutatavate ravimite komitee taotluse tagasivõtmise ajal põhjust ettevaatlikkuseks ning oli esialgsel seisukohal, et Gastromotalile ei või anda mao tühjenemise aeglustumise diagnoosimiseks müügiluba.
English: What was Gastromotal expected to be used for?
Estonian: Milleks kavatseti Gastromotali kasutada?
English: The CHMP was concerned that the reliability and usefulness of Gastromotal in diagnosing delayed stomach empting had not been shown.
Estonian: Inimtervishoius kasutatavate ravimite komitee nägi põhjust ettevaatlikkuseks sellepärast, et Gastromotali usaldusväärsust ja kasulikkust mao tühjenemise aeglustumise diagnoosimiseks ei olnud tõestatud.
English: The effects of Gastromotal were first tested in experimental models before being studied in humans.
Estonian: Enne uuringuid inimestel kontrolliti Gastromotali toimet muude katsetega.
English: QUESTIONS AND ANSWERS ON THE WITHDRAWAL OF THE MARKETING APPLICATION for GASTROMOTAL
Estonian: TEAVE MÜÜGILOA TAOTLUSE TAGASIVÕTMISE KOHTA
English: List of the names, pharmaceutical forms, strengths of the medicinal products, routes of administration, marketing authorisation holders in the Member States
Estonian: Ravimite nimetuste, ravimvormide, tugevuste, manustamisviiside ja müügiloa hoidjate loetelu liikmesriikides
English: D-85540 Haar
Estonian: D-85540 Haar Germany
English: Bucureşti-Ploieşti Nr.1A, Clădirea C1, Etaj 3, Sector 1, Bucureşti
Estonian: Bucureşti-Ploieşti Nr.1A, Clădirea C1, Etaj 3, Sector 1, Bucureşti Romania
English: Pelham House South County Business Park Leopardstown
Estonian: Pelham House South County Business Park
English: Quinta da Fonte Edifício Vasco da Gama, 19 P.O.
Estonian: Quinta da Fonte Edifício Vasco da Gama,
English: 2770-192 Paço de Arcos Portugal
Estonian: Porto Salvo 2770-192 Paço de Arcos
English: Via Vitorchiano, 151 - 00189 Roma
Estonian: Via Vitorchiano, 15100189 Roma Italy
English: Hertford Road, Hoddesdon, Hertfordshire EN11 9BU United Kingdom
Estonian: Hertford Road, Hoddesdon, Hertfordshire EN11 9BU
English: Euro Platz 2 1120 Wien Austria
Estonian: 1120 Wien
English: Merck Sharp & Dohme, UAB, Kęstučio 59/27, LT-08124 Vilnius
Estonian: Kęstučio 59/27, LT-08124 Vilnius
English: Primaxin IV 500mg Injection 500mg
Estonian: Primaxin IV 500mg Injection
English: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A, Viale Shakespeare, 47 00144 Roma
Estonian: Viale Shakespeare, 47 00144 Roma Italy
English: Merck Sharp & Dohme B.V. Waarderweg 39, Haarlem, P.O.Box 581, 2003 PC Haarlem The Netherlands
Estonian: Waarderweg 39, Haarlem, P.O.Box 581, 2003 PC Haarlem The Netherlands
English: Merck Sharp & Dohme B.V. Waarderweg 39, 2031 BN Haarlem, P.O.Box 581, 2003 PC Haarlem
Estonian: Waarderweg 39, 2031 BN Haarlem, P.O.Box 581, 2003 PC Haarlem The Netherlands
English: MSD SHARP & DOHME GMBH Lindenplatz 1
Estonian: MSD SHARP & DOHME GMBH
English: Powder for solution for infusion Intravenous infusion
Estonian: Pulber infusioonilahuse kontsentraadi valmistamiseks Intravenoosne
English: Powder for suspension for parenteral use (IM)
Estonian: Pulber süsteravimi lahuse valmistamiseks (i.m.)
English: 500 mg powder for solution for infusion 500 mg/500 mg Powder for solution for infusion Intravenous use
Estonian: 500 mg powder for solution for infusion 500 mg/500 mg Infusioonilahuse pulber
English: Merck Sharp & Dohme B.V. Waarderweg 39, 2031 BN Haarlem, The Netherlands
Estonian: Waarderweg 39, 2031 BN Haarlem, The Netherlands
English: Merck Sharp & Dohme B.V. Waarderweg 39, 2031 BN Haarlem
Estonian: Waarderweg 39, 2031 BN Haarlem
English: TIENAM 250 mg/250 mg, poudre pour perfusion
Estonian: TIENAM 250 mg/250 mg, poudre pour perfusion 250 mg/250 mg Infusioonilahuse pulber
English: Dublin 18
Estonian: Leopardstown Dublin 18
English: Porto Salvo
Estonian: Chaussée de Waterloo
English: 250 mg/250 mg Powder for infusion
Estonian: 250 mg ja 500 mg Infusioonilahuse pulber
English: Powder for concentrate for solution for infusion
Estonian: Pulber infusioonilahuse kontsentraadi valmistamiseks
English: Keytruda received a marketing authorisation valid throughout the EU on 17 July 2015.
Estonian: Keytruda on saanud müügiloa, mis kehtib kogu ELis, 17. juulil 2015.
English: What measures are being taken to ensure the safe and effective use of Keytruda?
Estonian: Mis meetmed võetakse, et tagada Keytruda ohutu ja efektiivne kasutamine?
English: Further information on Keytruda can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/keytruda.
Estonian: Lisateave Keytruda kohta on ameti veebilehel: ema.europa.eu/medicines/human/EPAR/keytruda.
English: The European Medicines Agency decided that Keytruda's benefits are greater than its risks and it can be authorised for use in the EU.
Estonian: Euroopa Ravimiamet otsustas, et Keytruda kasulikkus on suurem kui sellega kaasnevad riskid ja ravimi kasutamise võib ELis heaks kiita.
English: What is Keytruda and what is it used for?
Estonian: Mis on Keytruda ja milleks seda kasutatakse?
English: Why is Keytruda authorised in the EU?
Estonian: Miks Keytruda ELis heaks kiideti?
English: As for all medicines, data on the use of Keytruda are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, tehakse Keytruda kasutamise kohta pidevat järelevalvet.
English: Keytruda did not delay worsening of the disease compared with the other cancer medicines (time to disease worsening was 2 and 3 months respectively).
Estonian: Keytruda ei lükanud edasi haiguse süvenemist muude vähiravimitega võrreldes (haiguse süvenemise aeg oli vastavalt 2 ja 3 kuud).
English: When it is given with other cancer medicines, the dose is always 200 mg every three weeks.
Estonian: Kui seda manustatakse koos muude vähiravimitega, on annus alati 200 mg iga 3 nädala järel.
English: Other information about Keytruda
Estonian: Muu teave Keytruda kohta
English: When Keytruda is given alone the dose is either 200 mg every three weeks or 400 mg every six weeks.
Estonian: Kui Keytrudat manustatakse ainuravimina, on annus kas 200 mg iga 3 nädala järel või 400 mg iga 6 nädala järel.
English: The side effects with this medicine are manageable and are similar to those of various other cancer treatments.
Estonian: Selle ravimiga täheldatud kõrvalnähud on ohjatavad ja need on sarnased paljude muude vähiravimite kõrvalnähtudega.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Keytruda have also been included in the summary of product characteristics and the package leaflet.
Estonian: Keytruda ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on samuti lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: For more information about using Keytruda, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet Keytruda kasutamise kohta saate pakendi infolehelt või küsige oma arstilt või apteekrilt.
English: Keytruda can delay worsening of melanoma and improve survival.
Estonian: Keytruda võib edasi lükata melanoomi süvenemist ja parandada elumust.
English: What are the risks associated with Keytruda?
Estonian: Mis riskid Keytrudaga kaasnevad?
English: Moreover, the company will carry out analyses to better understand which patients are likely to benefit most from treatment with Keytruda.
Estonian: Ühtlasi teeb ettevõte analüüsid, et teha selgeks, millistele patsientidele on Keytruda-ravi kõige kasulikum.
English: Side effects reported with Keytruda are carefully evaluated and any necessary action taken to protect patients.
Estonian: Keytruda kõrvaltoimeid hinnatakse hoolikalt ja patsientide kaitseks võetakse vajalikke meetmeid.
English: The company that markets Keytruda will provide patients with an information pack and alert card to inform them about the risks of potential immune-related side effects and give instructions on when to contact their doctor if they experience symptoms.
Estonian: Keytruda annab patsientidele teabepakme ja ohutuskaardi, millel on teave võimalike immuunsüsteemiga seotud kõrvalnähtude riski kohta ja juhised võtta sümptomite tekkimisel ühendust arstiga.
English: Keytruda (pembrolizumab)
Estonian: Keytruda (pembrolisumaab)
English: The side effects of Keytruda are mostly related to the activity of the immune system, which may cause inflammation of body organs and tissues and can be serious, although most side effects resolve with appropriate treatment or on stopping Keytruda.
Estonian: Keytruda kõrvalnähud on valdavalt seotud immuunsüsteemi aktiivsusega, mis võib põhjustada elundites ja kudedes põletikku, mis võib olla raske, kuigi enamik kõrvalnähte laheneb asjakohase raviga või Keytruda manustamise lõpetamisel.
English: How is Keytruda used?
Estonian: Kuidas Keytrudat kasutatakse?
English: In addition, the company will provide the final results of studies with Keytruda to confirm the longterm benefits of the medicine.
Estonian: Ettevõte esitab ka ravimi pikaajalise kasulikkuse tõendamiseks Keytruda uuringute lõpptulemused.
English: Some cancers can make a protein (PD-L1) that combines with PD-1 to switch off the activity of certain cells of the immune system (the body's natural defences) preventing them from attacking the cancer.
Estonian: Teatud vähiliigid toodavad valku (PD-L1), mis PD-1-ga ühinedes lülitab välja immuunsüsteemi (organismi looduslikud kaitsemehhanismid) teatud rakkude aktiivsuse, takistades neil vähki hävitada.
English: Keytruda partially or completely clears cancer cells in classical Hodgkin lymphoma that has not improved or had returned after treatment with brentuximab vedotin, with or without an autologous stem cell transplantation.
Estonian: Keytruda kõrvaldab osaliselt või täielikult vähirakud patsientidel, kellel on klassikaline Hodgkini lümfoom, mis ei ole reageerinud ravile brentuksimaabvedotiiniga koos autoloogsete tüvirakkude siirdamisega või ilma või mis on taastekkinud pärast seda ravi.
English: In some patients, tumours have to produce a high level of PD-L1 for the medicine to be effective.
Estonian: Mõnel patsiendil peab kasvaja ravimi toimimiseks tootma suures koguses valku PD-L1.
English: • classical Hodgkin lymphoma, a cancer of the white blood cells,
Estonian: • klassikaline Hodgkini lümfoom (vere valgeliblede teatud vähk);
English: At 18 months, 81% of the patients given the combination were alive, compared with 71% in the sunitinib group.
Estonian: 18 kuu pärast oli elus 81% kombinatsioonravi ja 71% sunitiniibi kasutanud patsientidest.
English: A third study in 1,019 patients who had had surgery and who were at high risk for their cancer coming back compared Keytruda to placebo (a dummy treatment).
Estonian: Kolmandas uuringus, milles osales 1019 opereeritud patsienti, kellel esines suur vähi taastekke risk, võrreldi Keytrudat platseeboga (näiv ravim).
English: For the full list of side effects and restrictions with Keytruda, see the package leaflet.
Estonian: Keytruda kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: By blocking PD-1, pembrolizumab stops the cancer switching off these immune cells, thereby increasing the immune system's ability to kill the cancer cells.
Estonian: Retseptorit PD‑1 blokeerides ei lase pembrolisumaab vähil nende immuunrakkude aktiivsust välja lülitada, suurendades nii immuunsüsteemi võimet hävitada vähirakke.
English: The average time that patients lived without their disease getting worse again was around 11 months.
Estonian: Patsientide keskmine progresseerumiseta elumus oli ligikaudu 11 kuud.
English: How does Keytruda work?
Estonian: Kuidas Keytruda toimib?
English: A study looked at 542 patients previously treated with platinum-based medicines who received either Keytruda or another cancer medicine chosen by the doctor (paclitaxel, docetaxel or vinflunine).
Estonian: Uuringus uuriti varem plaatinapõhist keemiaravi saanud 542 patsienti, kes said kas Keytrudat või arsti valitud muud vähiravimit (paklitakseel, dotsetakseel või vinfluniin).
English: The most common side effects of Keytruda given alone (which may affect more than 1 in 5 people) are tiredness, nausea (feeling sick) and diarrhoea.
Estonian: Keytruda ainuravimina kasutamisel on kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 5st) väsimus, iiveldus ja kõhulahtisus.
English: Results from a study of 540 previously treated patients with melanoma showed that 2 years after start of treatment, the disease had not worsened in 16% of patients treated with Keytruda compared with less than 1% of patients treated with chemotherapy.
Estonian: Tulemused uuringust, milles osales 540 varem ravitud melanoomiga patsienti, näitasid, et patsiente, kellel 2 aastat pärast ravi algust ei olnud haigus süvenenud, oli Keytrudaga ravitud patsientidest 16% ning keemiaravi saanutest alla 1%.
English: Keytruda is also used to help prevent the cancer from coming back after patients had surgery to remove melanoma (adjuvant therapy).
Estonian: Keytrudat kasutatakse ka vähi taastekke ennetamiseks pärast melanoomi eemaldamise operatsiooni (adjuvantravi).
English: What benefits of Keytruda have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Keytruda kasulikkus?